This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Bristol-Myers Squibb Company

Drug Names(s): Carbidopa-Levodopa

Description: Sinemet is a combination of levodopa, a precursor to dopamine, and carbidopa, which inhibits the enzyme DDC from metabolizing levodopa before it reaches the brain. Levodopa is converted to dopamine via the action of a naturally occurring enzyme called DOPA decarboxylase (DDC). This occurs both in the peripheral circulation and in the central nervous system after levodopa has crossed the blood brain barrier. Activation of central dopamine receptors improves the symptoms of Parkinson's Disease, however, activation of peripheral dopamine receptors causes nausea and vomiting. For this reason levodopa is usually administered in combination with a DOPA decarboxylase inhibitor, in this case carbidopa, which does not cross the blood brain barrier but prevents peripheral conversion of levodopa to dopamine and thereby reduces the unwanted peripheral side-effects of levodopa. Use of carbidopa also increases the quantity of levodopa in the bloodstream that is available to enter the brain.

Partners: Merck & Co., Inc.

Sinemet News

Pink Sheet Roche/DuPont

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug